PROTAGONIST THERAPEUTICS INC (PTGX) Stock Price, Quote, News and Overview
NASDAQ:PTGX - Nasdaq - US74366E1029 - Common Stock - Currency: USD
PTGX Quote, Performance and Key Statistics
38.75
+0.26 (+0.68%)
The current stock price of PTGX is 38.75 USD. In the past month the price increased by 2.51%. In the past year, price increased by 36.06%.
PTGX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About PTGX
Company Profile
Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 126 full-time employees. The company went IPO on 2016-08-11. The firm uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).
Company Info
PROTAGONIST THERAPEUTICS INC
7707 Gateway Blvd Ste 140
Newark California CALIFORNIA 94560 US
CEO: Dinesh V. Patel
Employees: 125
Company Website: https://www.protagonist-inc.com/
Investor Relations: https://www.protagonist-inc.com/events-presentations
Phone: 15104740170
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
What is the stock price of PROTAGONIST THERAPEUTICS INC today?
The current stock price of PTGX is 38.75 USD. The price increased by 0.68% in the last trading session.
What is the ticker symbol for PROTAGONIST THERAPEUTICS INC stock?
The exchange symbol of PROTAGONIST THERAPEUTICS INC is PTGX and it is listed on the Nasdaq exchange.
On which exchange is PTGX stock listed?
PTGX stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROTAGONIST THERAPEUTICS INC stock?
16 analysts have analysed PTGX and the average price target is 60.18 USD. This implies a price increase of 55.3% is expected in the next year compared to the current price of 38.75. Check the PROTAGONIST THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROTAGONIST THERAPEUTICS INC worth?
PROTAGONIST THERAPEUTICS INC (PTGX) has a market capitalization of 2.31B USD. This makes PTGX a Mid Cap stock.
How many employees does PROTAGONIST THERAPEUTICS INC have?
PROTAGONIST THERAPEUTICS INC (PTGX) currently has 125 employees.
What are the support and resistance levels for PROTAGONIST THERAPEUTICS INC (PTGX) stock?
PROTAGONIST THERAPEUTICS INC (PTGX) has a support level at 38.64 and a resistance level at 38.76. Check the full technical report for a detailed analysis of PTGX support and resistance levels.
Is PROTAGONIST THERAPEUTICS INC (PTGX) expected to grow?
The Revenue of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to grow by 701.96% in the next year. Check the estimates tab for more information on the PTGX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy PROTAGONIST THERAPEUTICS INC (PTGX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PTGX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PTGX, evaluating the profitability, health, valuation and growth aspects
- PROTAGONIST THERAPEUTICS INC (PTGX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROTAGONIST THERAPEUTICS INC (PTGX) Sales and EPS estimates to see what analysts future expectations are.
- PROTAGONIST THERAPEUTICS INC (PTGX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROTAGONIST THERAPEUTICS INC (PTGX) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROTAGONIST THERAPEUTICS INC (PTGX) Stock Chart to make your own analysis
- PROTAGONIST THERAPEUTICS INC (PTGX) Latest news and press-releases to stay up to date.
Does PROTAGONIST THERAPEUTICS INC (PTGX) stock pay dividends?
PTGX does not pay a dividend.
When does PROTAGONIST THERAPEUTICS INC (PTGX) report earnings?
PROTAGONIST THERAPEUTICS INC (PTGX) will report earnings on 2025-03-18, after the market close.
What is the Price/Earnings (PE) ratio of PROTAGONIST THERAPEUTICS INC (PTGX)?
The PE ratio for PROTAGONIST THERAPEUTICS INC (PTGX) is 14.57. This is based on the reported non-GAAP earnings per share of 2.66 and the current share price of 38.75 USD. Check the full fundamental report for a full analysis of the valuation metrics for PTGX.
What is the Short Interest ratio of PROTAGONIST THERAPEUTICS INC (PTGX) stock?
The outstanding short interest for PROTAGONIST THERAPEUTICS INC (PTGX) is 6.62% of its float. Check the ownership tab for more information on the PTGX short interest.
PTGX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to PTGX. When comparing the yearly performance of all stocks, PTGX is one of the better performing stocks in the market, outperforming 75.99% of all stocks.
PTGX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to PTGX. While PTGX has a great health rating, its profitability is only average at the moment.
PTGX Financial Highlights
Over the last trailing twelve months PTGX reported a non-GAAP Earnings per Share(EPS) of 2.66. The EPS increased by 201.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 52.76% | ||
| ROA | 28.29% | ||
| ROE | 32.12% | ||
| Debt/Equity | 0 |
PTGX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to PTGX. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 282.62% and a revenue growth 701.96% for PTGX